Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis

Rosiglitazone as a Modulator of TLR4 and TLR3 Signaling Pathways in Rat Primary Neurons and Astrocytes

(2018) Dmitry Chistyakov et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Saroglitazar treatment prevents NASH, eliminates hepatocyte ballooning, and significantly improves serum LFTs, lipids and insulin resistance in DIAMOND(tm) mice compared to pioglitazone benchmark

(2018) R. Caffrey et al.   JOURNAL OF HEPATOLOGY

Characterization of a murine nonalcoholic steatohepatitis model induced by high fat high calorie diet plus fructose and glucose in drinking water

(2018) Xue-Jing Liu et al.   LABORATORY INVESTIGATION

Future therapy for non-alcoholic fatty liver disease

(2018) Danny Issa et al.   LIVER INTERNATIONAL

Role of microbiota-derived lipopolysaccharide in adipose tissue inflammation, adipocyte size and pyroptosis during obesity

(2018) Lars-Georg Hersoug et al.   NUTRITION RESEARCH REVIEWS

Pathology of non-alcoholic fatty liver disease

(2017) Pierre Bedossa   LIVER INTERNATIONAL

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

(2017) Mukul R. Jain et al.   LIVER INTERNATIONAL

Therapies in non-alcoholic steatohepatitis (NASH)

(2017) Abdul M. Oseini et al.   LIVER INTERNATIONAL

Incorporating Refractory Period in Mechanical Stimulation Mitigates Obesity-Induced Adipose Tissue Dysfunction in Adult Mice

(2017) Vihitaben S. Patel et al.   Obesity

Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression

(2016) Enas A. Abd El-Haleim et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD

(2016) Alexandra Montagner et al.   GUT

Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances

(2016) Jennie Ka Ching Lau et al.   JOURNAL OF PATHOLOGY

Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies

(2016) Giovanni Musso et al.   NATURE REVIEWS DRUG DISCOVERY

Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis

(2016) Takaomi Kessoku et al.   Scientific Reports

Saroglitazar for the treatment of dyslipidemia in diabetic patients

(2015) Shashank R Joshi   EXPERT OPINION ON PHARMACOTHERAPY

Role of APN and TNF-α in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease

(2015) X. Lin et al.   GENETICS AND MOLECULAR RESEARCH

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease

(2015) Michal Pawlak et al.   JOURNAL OF HEPATOLOGY

Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research

(2015) Joost Willebrords et al.   PROGRESS IN LIPID RESEARCH

LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease

(2015) Sara Ceccarelli et al.   Oncotarget

Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease

(2015) Sanja Stojsavljević   WORLD JOURNAL OF GASTROENTEROLOGY

Negatively regulating TLR4/NF-κB signaling via PPARα in endotoxin-induced uveitis

(2014) Wei Shen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice

(2014) Michal Pawlak et al.   HEPATOLOGY

Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model

(2014) AKITOSHI DOUHARA et al.   Molecular Medicine Reports

HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH

(2014) Samuele De Minicis et al.   PLoS One

Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease

(2014) Kouichi Miura   WORLD JOURNAL OF GASTROENTEROLOGY

Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches

(2013) Detlef Schuppan et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Hyperresponsivity to Low-Dose Endotoxin during Progression to Nonalcoholic Steatohepatitis Is Regulated by Leptin-Mediated Signaling

(2012) Kento Imajo et al.   Cell Metabolism

Melatonin alleviates lipopolysaccharide-induced hepatic SREBP-1c activation and lipid accumulation in mice

(2011) Xi Chen et al.   JOURNAL OF PINEAL RESEARCH

Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway

(2009) Motoharu Awazawa et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARα in high fat diet-induced obese mice

(2009) Sunhyo Jeong et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Bacterial Endotoxin Stimulates Adipose Lipolysis via Toll-Like Receptor 4 and Extracellular Signal-regulated Kinase Pathway

(2009) Luxia Zu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Fat and Beyond: The Diverse Biology of PPARγ

(2008) Peter Tontonoz et al.   Annual Review of Biochemistry

PPAR Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities

(2008) Mylène Perreault et al.   PPAR Research